Celldex Therapeutics, Inc.
CLDX
$32.53
$0.531.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.84% | -89.70% | -- | -70.78% | 345.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.84% | -89.70% | -- | -70.78% | 345.51% |
| Cost of Revenue | 38.75% | 60.49% | 39.03% | 36.56% | 66.18% |
| Gross Profit | -40.58% | -64.35% | -49.58% | -43.77% | -64.80% |
| SG&A Expenses | 5.81% | 16.35% | 6.29% | 13.84% | 18.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.13% | 52.57% | 33.08% | 32.31% | 55.61% |
| Operating Income | -34.58% | -55.56% | -41.23% | -37.87% | -54.50% |
| Income Before Tax | -46.27% | -72.68% | -59.17% | -57.92% | -63.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.27% | -72.68% | -59.17% | -57.92% | -63.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.27% | -72.68% | -59.17% | -57.92% | -63.97% |
| EBIT | -34.58% | -55.56% | -41.23% | -37.87% | -54.50% |
| EBITDA | -35.09% | -56.38% | -41.79% | -38.37% | -55.33% |
| EPS Basic | -45.87% | -72.33% | -58.86% | -57.03% | -45.42% |
| Normalized Basic EPS | -45.86% | -72.32% | -58.88% | -57.03% | -45.42% |
| EPS Diluted | -45.87% | -72.33% | -58.86% | -57.03% | -45.42% |
| Normalized Diluted EPS | -45.86% | -72.32% | -58.88% | -57.03% | -45.42% |
| Average Basic Shares Outstanding | 0.28% | 0.20% | 0.19% | 0.56% | 12.76% |
| Average Diluted Shares Outstanding | 0.28% | 0.20% | 0.19% | 0.56% | 12.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |